A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus
Zenas BioPharma (USA), LLC
190 participants
Sep 17, 2024
INTERVENTIONAL
Conditions
Summary
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
Placebo
Locations(82)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06559163